Abstract: A pixel structure, a liquid crystal display panel, a method of operating the liquid crystal display panel, and a display device are disclosed. The pixel structure includes a light shutter for switching between first and second states, wherein in the first and second states, the light shutter only allows first polarized light having a first polarization direction and second polarized light having a second polarization direction to pass, respectively; a birefringent filter for causing emergent paths of the first and second polarized light to be first and second paths, respectively; a first liquid crystal unit and a first color filter in the first path and corresponding to a first sub-pixel region, wherein the first color filter is at a light-emergent side of the first liquid crystal unit; and a second liquid crystal unit in the second path and corresponding to a second sub-pixel region.

Abstract: The present disclosure relates to a belt driven system. The belt driven system may include a master pulley, a slave pulley, a belt around the master pulley and the slave pulley, a tension pulley configured to tension the belt, and a position adjusting device configured to automatically adjust a position of the tension pulley based on an interaction of the tension pulley and the belt.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGR5 modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use. The present invention relates to a process for the preparation of a compound (II) and its salts and derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of FXR and TGR5 modulators. The present invention also relates to a process for the preparation of a compound (III) and its diethylamine salt.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: A high-precision frequency measuring system and method. The system includes: an analog-to-digital conversion module for receiving an analog intermediate frequency signal to convert the analog intermediate frequency signal into a digital intermediate frequency signal; a frequency mixing module for generating two orthogonal local carriers to convert the digital intermediate frequency signal to a digital baseband signal; an extraction filter module for performing low-pass filtering and extraction of the digital baseband signal, so as to reduce a data rate; a Fourier transform module for obtaining a frequency domain signal; a frequency measurement module for obtaining a first frequency measurement value; a scanning module for obtaining a scanned second frequency measurement value; and a selector for selecting either the first frequency measurement value or the second frequency measurement value as a result of frequency measurement. The system and method can improve the accuracy of frequency measurement.

Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

Abstract: The present invention relates to an optical module and optical module system using the same. The optical module comprises a transceiving unit, an antenna and an MCU. The transceiving unit receives control commands from one or more control computers via the antenna and transfers them to the MCU. Then the MCU processes the control commands and provides feedback information to the one or more control computers through the transceiving unit. In the optical module of the present invention, as a result of an additional IOT wireless unit, the optical module is capable of communicating with remote control computers, thereby achieving remote testing and control for optical modules, instead of using conventional control methods for optical modules.

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: A Gland Seal End Plug closure for a nuclear fuel rod cladding composed of silicon carbide or other materials that cannot be welded. The sealant is, preferably, made from one or more forms of pure graphite and the ram, seat and other components of the Gland Seal End Plug are formed from high temperature metallic or ceramic materials.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).

Abstract: The present disclosure provides a method and system for identifying plant species based on hyperspectral data, wherein the method includes: performing atmospheric radiation correction for the hyperspectral data of plants to be identified adopting Linear Regression method, to obtain corrected hyperspectral data, wherein, the hyperspectral data of the plants to be identified are collected by a hyperspectral ground object spectrometer provided within an unmanned aerial vehicle (UAV); performing external parameter orthogonalisation (EPO) processing for the corrected hyperspectral data; performing first order differential processing for the EPO processed hyperspectral data, to obtain hyperspectral data highlighting absorption peak information; performing discrete wavelet transformation processing for the hyperspectral data highlighting the absorption peak information, to obtain wavelet coefficients corresponding to the plants to be identified.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.